Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Integra Lifesciences ( (IART) ) just unveiled an update.
On December 11, 2025, Integra LifeSciences announced the adoption of a change in control severance program effective January 1, 2026, for certain executives, including key figures like Lea Knight and Robert T. Davis, Jr. This program, which renews the expiring one, offers severance packages and benefits in the event of employment termination following a company control change by December 31, 2026. The program includes lump sum payments, COBRA premium subsidies, and outplacement services, with provisions to avoid excise tax penalties. The term of the program extends automatically upon a change in control or qualifying termination, impacting the company’s executive retention strategy and stakeholder interests.
The most recent analyst rating on (IART) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.
Spark’s Take on IART Stock
According to Spark, TipRanks’ AI Analyst, IART is a Neutral.
Integra Lifesciences’ overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant profitability challenges and bearish technical indicators. Valuation metrics further reflect the company’s struggles, with a negative P/E ratio and no dividend yield. Despite some operational efficiencies highlighted in the earnings call, the overall outlook remains cautious.
To see Spark’s full report on IART stock, click here.
More about Integra Lifesciences
Integra LifeSciences Holdings Corporation operates in the medical technology industry, focusing on providing products and services related to tissue technologies and specialty surgical solutions. The company is known for its innovative solutions in healthcare, particularly in areas like tissue regeneration and surgical devices, with a market focus on enhancing patient care and surgical outcomes.
Average Trading Volume: 1,056,728
Technical Sentiment Signal: Sell
Current Market Cap: $1.06B
Learn more about IART stock on TipRanks’ Stock Analysis page.